LONDON, May 1, 2026, 17:58 BST
- Spirax Group dropped 0.98% by the London close. The FTSE 100 slipped 0.14%.
- Spirax Group plans to deliver a trading update and convene its annual meeting on May 13.
- In March, the company outlined a 2026 goal for organic growth alongside further margin improvement, so the next results will put both demand and cost management under the spotlight.
Spirax Group shares dipped in London trading on Friday, Barclays quoting the stock off by 70 pence, or 0.98%, with a sell price of 7,096p and buy at 7,106p at 16:35. The FTSE 100 edged down 0.14%.
This shift brings the Cheltenham-based steam systems and fluid technology manufacturer back into the spotlight ahead of its May 13 trading update and annual general meeting—the next big date on the calendar following its March full-year results.
This is key—Spirax has guided investors to expect “good organic growth and further margin progress” for 2026. By organic growth, they’re talking results stripped of currency swings, takeovers, or asset sales, offering a clearer window into true demand. Investegate
No new Spirax trading statement has appeared on the regulatory feed in the past day. The most recent filings, dated April 8, include the annual report, AGM notice, and a director/PDMR shareholding disclosure.
Spirax posted 2025 revenue of £1.70 billion in March, a 5% organic rise, with adjusted operating profit climbing 6% to £339.9 million. But statutory operating profit slipped 13% to £265.4 million, weighed by one-off restructuring charges. The company said its restructuring programme wrapped up, delivering £40 million in annualised savings.
Back then, Chief Executive Nimesh Patel pointed to Spirax making headway despite a “volatile and uncertain macroeconomic backdrop.” For the full year, the group remains confident, expecting “good organic growth and further margin progress.” Investegate
The divisions aren’t all moving in lockstep. Steam Thermal Solutions managed just a 1% organic lift for 2025. Electric Thermal Solutions climbed 11%. Watson-Marlow Fluid Technology Solutions was up 6%, driven by a rebound from Biopharm—read pharmaceutical and biotech customers—and also stronger orders from Semicon, or semiconductor equipment makers.
Andrew Mines, Electric Thermal Solutions’ managing director, labeled 2025 as a year showing “strong progress” in the annual report. Over at Watson-Marlow, managing director Stuart Roby highlighted the Biopharm market’s rebound and noted sector-led selling. Spirax Group
It’s not all moving in the same direction for UK industrials. On Friday, Rotork reported a low single-digit organic revenue increase for the first quarter, but noted that order intake slipped by a similar margin. The company is holding steady on its guidance for 2026, though it pointed to delayed oil and gas projects in the Middle East.
Still, things could shift. Spirax pointed to sluggish large-project activity in China and political instability in Korea dragging on Steam Thermal Solutions in 2025. Currency fluctuations shaved 3% off sales and knocked adjusted operating profit down by 4%. If Biopharm rebounds more slowly, China project demand softens further, or the pound strengthens, management may find it tougher to deliver on those targeted margin gains.
Investors are set to decide on changes to the directors’ pay policy and an amended share award scheme at the AGM on May 13. The gathering gets underway at 3:00 p.m. at the registered office in Cheltenham.
Spirax has been on the London market since 1959, and joined the FTSE 100 in 2018. The company focuses on thermal energy and fluid tech, split across three core divisions: Steam Thermal Solutions, Electric Thermal Solutions, and Watson-Marlow Fluid Technology Solutions. Operating in close to 70 countries, Spirax says it’s serving upwards of 100,000 customers.
